Objectives: This research emphasizes validating the HPLC, HPTLC, and UV-visible techniques for the simultaneous quantitative measurement of Moxifloxacin (MOX) and Tolfenamic Acid (TA) in veterinary formulations. Materials and Methods: The UV spectrophotometric analysis was performed at 291 nm for moxifloxacin and 272 nm for tolfenamic acid. For HPLC, chromatographic separation was achieved using a gradient technique on a reverse-phase C18 ODS column (250×4.6 mm, 5 µm particle size) with a mobile phase comprising 2% orthophosphoric acid and an acetonitrile with ratio of 80:20, with a 1 mL/min flow rate. Detection was accomplished at 254 nm. For HPTLC, separation was performed on pre-coated silica gel 60 F254 plates using a mobile phase of acetonitrile: water: formic acid: methanol:30% ammonia (8:1:1:1:2 v/v). Densitometric assessment for separate zones was performed at 230 nm. Results: The HPLC analysis of the current method exhibits the linearity range from 2 to 12 µg/mL for moxifloxacin and 1 to 6 µg/mL for tolfenamic acid in HPLC, 8 to 20 µg/spot for moxifloxacin and 4 to 9 µg/spot for tolfenamic acid in HPTLC, and 6 to 42 µg/mL for MOX and 3 to 21 µg/mL for TA in UV spectrophotometry. The methods were found to be accurate; recovery was achieved from 98 to 102%. The Relative Standard Deviation (RSD) for precision was found to be less than 2%. Conclusion: The proposed methods were successfully applied to the determination of MOX and TA in both bulk and veterinary tablet formulations. The methods were validated in accordance with ICH Q2-(R1) guidelines.